<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2281">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366089</url>
  </required_header>
  <id_info>
    <org_study_id>110/2020</org_study_id>
    <nct_id>NCT04366089</nct_id>
  </id_info>
  <brief_title>Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora</brief_title>
  <acronym>PROBIOZOVID</acronym>
  <official_title>Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roberto Poscia MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Policlinico Umberto I</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Italy was the first European country affected by a severe outbreak of the Severe Acute
      Respiratory Syndrome - CoronaVirus-2 (SARS-CoV-2) epidemic emerged from Wuhan region (China),
      with a high morbidity and mortality associated with the disease.

      In light of its pandemic spread and the very limited therapeutic options, COronaVIrus Disease
      19 (COVID-19) is considered an unprecedented global health challenge. Therefore, the
      evaluation of new resources, designed in the first instance for other pathologies but
      potentially active against COVID-19, represents a priority in clinical research.

      This is an interventional, non-pharmacological, open, randomized, prospective, non-profit
      study on the adjuvant use of oxygen ozone therapy plus probiotic supplementation in the early
      control of disease progression in patients with COVID-19.

      Contextually, all patients are treated with the current standard of care on the basis of the
      interim guidelines of the Italian Society of Infectious and Tropical Diseases.

      The main purpose of the study is to evaluate the effectiveness of an ozone therapy-based
      intervention (accompanied by supplementation with probiotics) in containing the progression
      of COVID-19 and in preventing the need for hospitalization in intensive care units.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies analyzed the mechanisms by which ozone therapy could combat viral infections.
      In particular, 1) the improvement of the release of oxygen in the peripheral tissues, 2) the
      anti-inflammatory action 3) a virucidal activity have been described.

      In view of these properties, a number of international clinical trials on the topic are
      currently ongoing.

      Hospitalization, dietary changes, use of antibiotics and systemic inflammation related to
      COVID-19 are all variables that contribute to changes in the intestinal and lung microbiota
      with significant repercussions on the outcomes of the disease. Furthermore, the use of ozone
      therapy could also lead to a modification of the microbial flora. Probiotic supplementation
      can help to correct these issues.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta in the number of patients requiring orotracheal intubation despite treatment</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta of crude mortality</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta of length of stay for patients in hospital</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of interleukin (IL)-1</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of IL-6</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of IL-10</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of Tumor Necrosis Factor (TNF)-alpha</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of CD8+ CD38/ HLA-DR</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of fecal calprotectin</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of lipopolysaccharide (LPS)</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of zonulin</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta in the value of alpha1-antitrypsin</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>COVID</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen-ozone and probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen-ozone therapy, probiotic supplementation plus standard of care
Oxygen-ozone therapy: systemic autohemotherapy (twice a day).
Probiotic supplementation: SivoMixx 200 billion (six sachets twice a day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxygen-ozone therapy, probiotic supplementation and Standard of care</intervention_name>
    <description>- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days</description>
    <arm_group_label>Oxygen-ozone and probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SivoMixx (200 billion)</intervention_name>
    <description>Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)</description>
    <arm_group_label>Oxygen-ozone and probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)</description>
    <arm_group_label>Oxygen-ozone and probiotic</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
    <description>dose: 200 mg, 1 cp x 2 / day</description>
    <arm_group_label>Oxygen-ozone and probiotic</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Nasopharyngeal swab positive for COVID-19

          -  COVID-19 stages I - II - III (*1)

          -  Hospitalization in the Department of Infectious Diseases

        Exclusion Criteria:

          -  COVID-19 stages IV - V - VI (*1)

          -  Hospitalization in Intensive Care Units

          -  Pregnancy

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Patients who deny consent to the proposed treatment

          -  Inability to provide informed consent

          -  Contraindications to performing oxygen-ozone therapy

          -  hyperhomocysteinemia

          -  favism or thyroiditis

          -  coagulopathies

          -  neurodegenerative diseases

          -  angina (in particular Prinzmetal's angina) or with previous myocardial infarction

        (*1) Compliant with indications published by:

        Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care (SIAARTI).

        Care pathway for the patient with COVID-19.

        Section 2 - Recommendations for local management of the critically ill patient - Version 2

        Available on
        http://www.siaarti.it/SiteAssets/News/COVID19%20-%20documenti%20SIAARTI/Percorso%20COVID-19
        %20-%20Sezione%202%20-%20Raccomandazioni%20per%20la%20gestione%20locale%20-%20Rev%202.0.pdf

        Last accessed 20/04/2020

        Posted on 26.03.2020

        On page 2 of the previous document :

        &quot;6 identified stages:

          -  sick disease - mild COVID-19 (I stage)

          -  light pneumonia - mild COVID-19 (II stage)

          -  serious pneumonia - severe COVID-19 (III stage)

          -  Acute respiratory distress syndrome (ARDS) - critical COVID-19 (IV stage)

          -  sepsis - critical COVID-19 (V stage)

          -  septic shock - critical COVID-19 (VI stage)&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Pugliese, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome Sapienza - Policlinico Umberto I Rome (Italy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Pugliese, MD, PhD</last_name>
    <phone>00390649978024</phone>
    <email>f.pugliese@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio Araimo, MD</last_name>
    <email>f.araimo@policlinicoumberto1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Francesco Pugliese</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Pugliese, MD PhD</last_name>
      <phone>00390649978024</phone>
      <email>f.pugliese@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Araimo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmela Imperiale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Tordiglione, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio M Mastroianni, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriella d'Ettorre, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giancarlo Ceccarelli, MD PhD MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Calò, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vera MAuro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serena Zancla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregorio Egidio Recchia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.chictr.org.cn/showproj.aspx?proj=49947</url>
    <description>Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)</description>
  </link>
  <link>
    <url>http://www.chictr.org.cn/showproj.aspx?proj=49737</url>
    <description>A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)</description>
  </link>
  <link>
    <url>http://www.chictr.org.cn/showproj.aspx?proj=49747</url>
    <description>A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)</description>
  </link>
  <results_reference>
    <citation>Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C, Baeza J. Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19. Rev Esp Anestesiol Reanim. 2020 May;67(5):245-252. doi: 10.1016/j.redar.2020.03.004. Epub 2020 Apr 14. English, Spanish.</citation>
    <PMID>32303365</PMID>
  </results_reference>
  <results_reference>
    <citation>Conti P, Gallenga CE, Tetè G, Caraffa A, Ronconi G, Younes A, Toniato E, Ross R, Kritas SK. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents. 2020 March-April,;34(2):333-338. doi: 10.23812/Editorial-Conti-2.</citation>
    <PMID>32228825</PMID>
  </results_reference>
  <results_reference>
    <citation>Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2020 Aug 10. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK554776/</citation>
    <PMID>32150360</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, Li J, Wang H, Yu L, Huang H, Qiu Y, Wei G, Fang Q, Zhou J, Sheng J, Liang T, Li L. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(1):0. Chinese.</citation>
    <PMID>32096367</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Policlinico Umberto I</investigator_affiliation>
    <investigator_full_name>Roberto Poscia MD, PhD</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Oxygen-ozone therapy</keyword>
  <keyword>gut microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

